MRNA-seq of HCC1954 siControl and siRNF40
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB38971 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:mRNA-seq of HCC1954 siControl and siUSP22
| PRJEB34048 | ENA
Project description:The analysis of genes affected upon USP22 kcnockdown in HCC1954 cells
2020-08-31 | E-MTAB-8256 | biostudies-arrayexpress
Project description:The analysis of genes affected upon RNF40 knockdown in HCC1954 cells
2020-11-16 | E-MTAB-9234 | biostudies-arrayexpress
Project description:LncRNA and mRNA expression profiling of Hepatocellular carcinoma Huh7 when HINT1 knockdown. HINT1 is a novel tumor suppressor gene, which can regulate the transcription of a variety of cancer-related genes, and its regulation networks is poorly understood in hepatocellular carcinoma. We used the total RNA from siControl and siHINT1 Huh7 cells to analyze the differentially expressed lncRNA and mRNA which were regulated by HINT1, and further explored the ceRNA network that HINT1 may involved.
2022-03-09 | GSE177624 | GEO
Project description:Transcriptional profiling of the prostate adenocarcinoma cell line PC-3 comparing control cells transfected with a pool of oligonucleotides control (siControl) with cells transfected a pool of oligonucleotides specific to inhibit ARHGAP21 expression (siARHGAP21). The efficiency of the transfection was checked with quantitative PCR and western blotting. Goal was to determine the effects of ARHGAP21 silencing on global PC-3 gene expression. Two-condition experiment, siControl vs. siARHGAP21 PC-3 cells with three biological samples of PC3 cells transfected with a pool of oligonucleotides control (siControl 1, 2 and 3) and three biological samples of PC3 cells transfected with a pool of oligonucleotides specific to inhibit ARHGAP21 (siARHGAP21 1, 2 and 3). For each sample (three siControl and three siARHGAP21), two technical replicates were performed (labelled with Cy3 or Cy5).
2012-12-31 | E-GEOD-37888 | biostudies-arrayexpress
Project description:Hepatocellular carcinoma Huh7: siHINT1 vs. siControl
| PRJNA737130 | ENA
Project description:Transcriptional profiling of the prostate adenocarcinoma cell line PC-3 comparing control cells transfected with a pool of oligonucleotides control (siControl) with cells transfected a pool of oligonucleotides specific to inhibit ARHGAP21 expression (siARHGAP21). The efficiency of the transfection was checked with quantitative PCR and western blotting. Goal was to determine the effects of ARHGAP21 silencing on global PC-3 gene expression.
2012-12-31 | GSE37888 | GEO
Project description:McGill EMC Release 4 for assay "mRNA-seq": Transcriptome profiling by high-throughput sequencing
| EGAD00001001291 | EGA
Project description:The intention was to detect genes that are determining trastuzumab efficiency in HER2-positive breast cancer cell lines with different resistance phenotypes. While BT474 should be sensitive to the drug treatment, HCC1954 is expected to be resistant due to a PI3K mutation. The cell line BTR50 has been derived from BT474 and was cultured to be resistant as well. Based on RNA-Seq data, we performed differential expression analyses on these breast cancer cell lines with and without trastuzumab treatment. In detail, five separate tests were performed, namely resistant cells vs. wild type, i.e. HCC1954 and BTR50 vs. BT474, respectively, and untreated vs. drug treated cells. The significant genes of the first two tests should contribute to resistance. The significant genes of the test BT474 vs. its drug treated version should contribute to the trastuzumab effect. To exclude false positives from the combined gene set (#64), we removed ten genes that were also significant in the test BTR50 vs. its drug treated version. This way we ended up with 54 genes that are very likely to determine trastuzumab efficiency in HER2-positive breast cancer cell lines. mRNA profiles of human breast cancer cell lines were generated by deep sequencing using Illumina HiSeq 2000. The cell lines BT474 and HCC1954 were analyzed with and without trastuzumab treatment. HCC1954 is known to be trastuzumab resistant. Additionally, the cell line BTR50 was generated as resistant version of BT474, and was analyzed with and without trastuzumab as well.
2015-04-21 | E-GEOD-55005 | biostudies-arrayexpress